{
    "nct_id": "NCT03726307",
    "official_title": "Allogeneic Regulatory Dendritic Cell (DCreg) Therapy in Live-Donor Renal Transplant Recipients",
    "inclusion_criteria": "Donor Eligibility Criteria:\n\n* Able to understand and provide informed consent;\n* Meets all standard institutional criteria for kidney donation and Health Agency compliance with kidney donation regulations;\n* For females of childbearing potential, a negative urine or serum pregnancy test;\n* Negative for tuberculosis by either a negative:\n\n  * Purified Protein Derivative (PPD) test or\n  * Result using an approved interferon-gamma release assay (IGRA) blood test, such as QuantiFERON®-Gold TB or T-SPOT.TB assay,\n\n    * Unless the participant has completed treatment for latent tuberculosis, and has a negative chest x-ray.\n    * Note:\n\n      1. PPD or IGRA testing documented to have been performed within 52 weeks before transplant is acceptable\n      2. Prior recipients of a Bacille Calmette-Guérin (BCG) vaccination must follow the same requirements\n* Negative for Human Immunodeficiency Virus type 1 (HIV) -1 (antigen and Nucleic Acid Testing (NAT)), HIV-2, Human T-cell leukemia virus type 1 (HTLV-1), and HTLV-2;\n* Negative for hepatitis C (antibody and NAT), hepatitis B (surface antigen and core antibody), and Treponema pallidum infection;\n* Negative for West Nile Virus;\n* Negative health history for risk factors related to Zika Virus and Creutzfeldt-Jakob disease;\n* No live vaccines within 8 weeks prior to leukapheresis;\n* No medical condition(s) that the investigator deems incompatible with participation in the trial; and\n* No use of investigational drugs within 12 weeks of participation.\n\nRecipient Inclusion Criteria:\n\n* Must be able to understand and provide informed consent;\n* Is undergoing first living donor renal transplant;\n* For females of childbearing potential, a negative urine or serum pregnancy test upon study entry and agreement to use effective contraception according to Health Agency oversight standards throughout the interval of study participation;\n* Cytomegalovirus (CMV) seropositive or, if CMV seronegative must be receiving a kidney from a CMV seronegative donor;\n* Negative for tuberculosis by either negative:\n\n  * Purified Protein Derivative (PPD) test or\n  * Result using an approved interferon-gamma release assay (IGRA) blood test, such as QuantiFERON®-Gold TB or T-SPOT.TB assay.\n\n    * Exception: If the participant has completed treatment for latent tuberculosis, and has a negative chest x-ray.\n    * Note:\n\n      1. PPD or IGRA testing documented to have been performed within 52 weeks before transplant is acceptable.\n      2. Prior recipients of a Bacille Calmette-Guérin (BCG) vaccination must follow the same requirements as referenced above.\n* And meets all standard institutional criteria for kidney transplant.\n\nStudy\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Panel Reactive Antibody (PRA >20%);\n* Positive T or B Cell Flow Crossmatch prior to transplant;\n* Presence of donor specific antibody (DSA) ≥ to mean fluorescence intensity (MFI) of 1000, or DSA between 500 and 1000, if a specific shared epitope pattern is present;\n* Recipient of multi-organ transplant;\n* Any prior renal or extra-renal transplant;\n* Epstein-Barr Virus (EBV) Immunoglobulin G (IgG) seronegative status;\n* Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (HCV) antibody (if hepatitis C antibody positive, confirm negative infection by HCV RNA), or positivity for hepatitis B surface antigen;\n* History of malignancy other than non-melanomatous skin cancer;\n* High risk for recurrence of renal disease:\n\n  * Hemolytic Uremic Syndrome Thrombotic Thrombocytopenic Purpura (HUS-TTP),\n  * Focal Segmental Glomerular Sclerosis (FSGS), or\n  * Aggressive native kidney disease.\n* Significant coronary artery disease, Ejection Fraction <30% or prior acute myocardial infarction;\n* Compensated and decompensated cirrhosis of liver and/or portal hypertension;\n* Chronic Obstructive Pulmonary Disease requiring nasal oxygen, and/or pulmonary hypertension (mean pulmonary pressure >45mm/hg);\n* Any history of stroke with neurological deficit;\n* Any condition that, in the opinion of the investigator, confers excessive risk for participation in this phase 1 study;\n* Presence of a condition that requires treatment with an immunosuppressive agent, other than a physiologic dose of corticosteroid;\n* Live vaccines within 8 weeks prior to transplant;\n* Use of investigational drugs within 12 weeks of participation;\n* Women receiving a kidney from a man who has fathered her child(ren), whether or not carried to term; or\n* Women receiving a kidney from her biological child.",
    "miscellaneous_criteria": ""
}